<DOC>
	<DOCNO>NCT00091936</DOCNO>
	<brief_summary>Tuberculosis ( TB ) , bacterial infection common HIV infected people , major problem develop country . The purpose study test effectiveness combine treatment strategy use directly observe therapy ( DOT ) HIV infect patient TB . Participants recruit resource-poor community Durban , South Africa .</brief_summary>
	<brief_title>Effectiveness Directly Observed Therapy Combined HIV Tuberculosis Treatment Resource-limited Settings</brief_title>
	<detailed_description>TB common serious infectious complication associate HIV sub-Saharan Africa also common cause death among HIV infect patient develop country . Furthermore , TB HIV infect person accelerates progression HIV disease hasten death . This study evaluate combine TB antiretroviral treatment ( ART ) strategy utilize DOT HIV infect people coinfected TB . This study compare two treatment strategy : TB HIV medication give concurrently ( integrated arm ) TB treatment complete first , follow HIV treatment ( sequential arm ) . This study two part . The entire study last 24 month participant randomly assign one two arm . Arm 1 ( integrated arm ) participant receive didanosine ( ddI ) , efavirenz ( EFV ) , lamivudine ( 3TC ) daily concurrent standard TB therapy . ART TB medication provide DOT weekday ; participant take medication without DOT weekend . Arm 1 participant also attend four 15- 20-minute session adherence study program study start , Week 2 , Month 2 , 1 3 week prior end TB therapy . Arm 2 ( sequential arm ) participant first receive DOT-provided TB treatment alone . After completion TB treatment , participant receive ddI , EFV , 3TC daily without DOT . Study visit first part study occur screen , study start , Weeks 1 , 2 , 3 , every month end first part study Month 12 . Study visit include blood collection , medical medication history assessment , physical exam , pill count . Patients ask complete adherence questionnaire every study visit sexual behavior survey quality life questionnaire study start Month 6 .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Tuberculosis</mesh_term>
	<mesh_term>Didanosine</mesh_term>
	<mesh_term>Efavirenz</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<criteria>Inclusion Criteria First Part Study : HIV infect TB infect Currently receive standard antiTB therapy ( isoniazid , rifampicin , ethambutol , pyrazinamide ) Currently participate Prince Cyril Zulu CDC Directly Observed Therapy ( DOT ) program receive treatment daily either community supervise community nurse train health worker Intending stay area duration study Willing participate followup visit Willing use acceptable form contraception Female participant must willing regular pregnancy test ART Exclusion Criteria First Part Study : Have 28 day cumulative ART prior study entry . Participants take mothertochild transmission ( MTCT ) postexposure prophylaxis ( PEP ) prevention treatment exclude . Less 10 day great 28 day since start current TB treatment Body temperature great 38.5 C ( 101.3 F ) Rash , nausea , vomit Grade 3 high Hospitalized refer hospitalization care treatment opportunistic infection , TB , cause screen enrollment CD4 count le 50 cells/microL within 28 day study entry TB meningitis TB spread blood organ lungs History prior TB treatment previous active TB episode unresponsive standard antiTB regimen History current AIDSdefining condition define World Health Organization ( WHO ) History current pancreatitis Peripheral neuropathy Grade 2 high Currently take certain medication Suspected multidrug resistant ( MDR ) TB Any condition , opinion investigator , may interfere study Participation study may interfere study Pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2007</verification_date>
	<keyword>Treatment Naive</keyword>
	<keyword>Directly Observed Therapy</keyword>
	<keyword>DOT</keyword>
	<keyword>TB</keyword>
</DOC>